天津医药

天津医药 ›› 2018, Vol. 46 ›› Issue (1): 104-109.doi: 10.11958/20170949

• 综述 • 上一篇    下一篇

骨保护素系统与冠状动脉粥样硬化性心脏病的研究进展

信佳言 1，丛洪良 2△，赵福梅 1，宋衍秋 1   

  1. １天津医科大学研究生院（邮编 300070）；2 天津市胸科医院
  • 收稿日期:2017-09-07 修回日期:2017-11-02 出版日期:2018-01-15 发布日期:2018-01-16
  • 通讯作者: 丛洪良 E-mail:hongliangcong@126.com
  • 作者简介:信佳言（1992），女，硕士在读，主要从事冠心病研究

Osteoprotegerin system and coronary atherosclerotic heart disease: an update

XIN Jia-yan1, CONG Hong-liang2△, ZHAO Fu-mei1, SONG Yan-qiu1   

  1. 1 Graduate School of Tianjin Medical University ，Tianjin 300070, China; 2 Tianjin Chest Hospital
  • Received:2017-09-07 Revised:2017-11-02 Published:2018-01-15 Online:2018-01-16

PDF (PC)

3611

摘要： 骨保护素（OPG）是肿瘤坏死因子（TNF）超家族的一种可溶性分泌型糖蛋白，与核因子 κB 受体活化因子配 体（RANKL）、核因子 κB 受体活化因子（RANK）以及肿瘤坏死因子相关凋亡诱导配体（TRAIL）共同组成骨保护素系 统。大量临床及实验研究证实骨保护素系统参与内皮功能调节、炎症反应、氧化应激及细胞凋亡等生理过程，其有 望成为冠心病发生、发展、严重程度及其远期预后的生物学标志物，为冠心病的早期诊断及治疗提供新的可行途径。 本文就骨保护素系统在冠心病发生、发展中的生物学效应、作用机制及未来的临床应用前景进行综述。

关键词: 冠状动脉狭窄, 分子作用机制, 综述, 骨保护素

Abstract: Osteoprotegerin (OPG), as a member of the tumor necrosis factor (TNF) superfamily, is a soluble secretary glycoprotein, which is accompanied with NF-κB receptor activator (RANK), NF-κB receptor activator ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to form osteoprotegerin system. A large number of clinical and experimental studies have confirmed that osteoprotegerin system participates in physiological processes such as endothelial function, inflammatory reaction, oxidative stress and apoptosis, which is expected to be a biomarker for the occurrence, development, severity and long-term prognosis of coronary heart disease. In this paper, we summarized the biological effects and mechanism of the osteoprotegerin system in the occurrence and development of coronary heart disease and its future clinical application.

Key words: coronary artery stenosis, molecular mechanism, review, osteoprotegerin